CRL · Earnings call · 2026Q2T · Full report

China Market Commentary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 10 · Surprise 6

Management described China as an important and evolving market and said Charles River has a strong research-models and services business there. The company is monitoring the increasing capabilities of Chinese CROs and the possibility that global biopharma companies expand in-house preclinical capabilities through Chinese R&D centers. Management said regulated safety-assessment work remains a minority of Chinese CRO activity and that global biopharma investments in China are currently concentrated more in early-stage research than regulated development. Charles River intends to differentiate its Western operations through services, speed, supply chain capabilities, and regulated-testing expertise.

Key facts

• Charles River believes global biopharma clients have progressed through restructuring and pipeline reprioritization over the last several years and that revenue from global biopharmaceutical clients continued to increase organically in the second quarter.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. states that regulated work, where most of its work is, has had very little influx into China so far.